This cytotoxic drug utilizes Molecular Templates an innovative Engineered Toxic Bodies (ETBs) drug delivery platform to trigger cell death. MT-3724 is being developed for the treatment of non-Hodgkin’s Lymphoma and harnesses the immunotherapy power of antibody receptor-specific targeting combined, a bacterial process for cell invasion that infects cancer cells with ribosomal inhibitors that strangle protein synthesis. MT-3724 Immunotoxin demonstrates a unique mechanism of action, packing a cytotoxic 1-2-3 cancer killing punch.
X-ray Crystallography Gallery
MT-3724’s Mechanism of Action
While targeting CD20 antigens using anti-CD20 FAB fragments is nothing new for oncology treatments, Molecular Templates is using a completely new and revolutionary approach to initiate a cytotoxic immune response. The ETB platform is robust, combining multiple unique mechanisms into a single immunotoxin.
- It targets cancer cells using anti-CD FABs
- Tags cancer cells for an immune response using viral antigen
- Kill tumor cells by stopping ribosomal protein synthesis, effectively halting nuclear function.
Molecular Templates explains:
“Molecular Templates has developed an engineered toxin body (ETB) platform, a next-generation recombinant immunotoxin scaffold based on the Shiga-like toxin A subunit (SLT-1A) specifically directed to cancer cells via antibody fragment binding domains. The ETB scaffold is engineered to force the internalization of receptors that typically do not internalize or internalize poorly. Molecular Templates’ lead compound, MT-3724, is the first immunotoxin targeting CD20 to enter the clinic and is currently in a phase I study for refractory non-Hodgkin’s Lymphoma.
Purchase 3D Print of MT-3724 Immunotoxin